EUVIMEDObjevte EUVIMED
Kohortenstudie

Albuminuria‐based stratification of end‐stage kidney disease progression and mortality with sodium‐glucose cotransporter 2 inhibitors ( SGLT2i ): A retrospective cohort study in type 2 diabetes and chronic kidney disease

Tien-Jyun Chang iD, Yen-Chieh Lee iD, Li-Chiu Wu, Chia-Hsuin Chang iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2024

DOI: 10.1002/phar.4615 ↗

At a glance

Kohortenstudie in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2024. Written by Tien-Jyun Chang and 3 co-authors. Institution: Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Major MEDLINE topics: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Albuminuria, Disease Progression. Cited 2 times so far (Crossref); 36 references. Funded by: National Science and Technology Council.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Clinical trials have shown the kidney‐protective benefits of sodium‐glucose cotransporter 2 inhibitors (SGLT2i). However, their real‐world impact, particularly across varying levels of albuminuria, remains less well understood. This study aimed to evaluate the association of SGLT2i, compared with other oral glucose‐lowering drugs, with end‐stage kidney disease (ESKD) progression in patients with type 2 diabetes and chronic kidney disease (CKD) stratified by urine albumin‐to‐creatinine ratio (UACR) levels.

Methods

Using data from a national database spanning from 2016 to 2021, the study included patients with type 2 diabetes and CKD with estimated glomerular filtration rates (eGFRs) below 60 mL/min/1.73 m 2 and who started on SGLT2i or other oral glucose‐lowering drugs. Patients were stratified into groups by UACR ≥300 mg/g and

Subjects

MeSH terms (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2AlbuminuriaDisease ProgressionKidney Failure, ChronicRenal Insufficiency, ChronicHumansMaleFemaleRetrospective StudiesMiddle AgedAgedCohort StudiesGlomerular Filtration Rate

Author keywords

albuminuriachronic kidney diseaseend‐stage kidney diseasemortalitysodium‐glucose transporter 2 inhibitorstype 2 diabetes

Substances

Sodium-Glucose Transporter 2 Inhibitors

Authors and institutions

  • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Department of Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Department of Family Medicine, Cathay General Hospital, Taipei, Taiwan.
  • Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.

ORCID profiles: Tien-Jyun Chang, Yen-Chieh Lee, Chia-Hsuin Chang

Funding

  • National Science and Technology Council

Cite

APA

Chang, T. J., Lee, Y. C., Wu, L. C., & Chang, C. H. (2024). Albuminuria‐based stratification of end‐stage kidney disease progression and mortality with sodium‐glucose cotransporter 2 inhibitors ( SGLT2i ): A retrospective cohort study in type 2 diabetes and chronic kidney disease. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.4615

Vancouver

Chang TJ, Lee YC, Wu LC, Chang CH. Albuminuria‐based stratification of end‐stage kidney disease progression and mortality with sodium‐glucose cotransporter 2 inhibitors ( SGLT2i ): A retrospective cohort study in type 2 diabetes and chronic kidney disease. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2024. doi:10.1002/phar.4615

BibTeX
@article{Chang2024,
  author = {Chang, Tien-Jyun and Lee, Yen-Chieh and Wu, Li-Chiu and Chang, Chia-Hsuin},
  title = {Albuminuria‐based stratification of end‐stage kidney disease progression and mortality with sodium‐glucose cotransporter 2 inhibitors ( SGLT2i ): A retrospective cohort study in type 2 diabetes and chronic kidney disease},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2024},
  doi = {10.1002/phar.4615}
}
Start for free →